Skip to content

ESC/EAS 2025 focused update: dyslipidaemias

International ESC/EAS Current

2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias

Mach F, et al. Eur Heart J. 2025;46:4359–4378
DOI 10.1093/eurheartj/ehaf190 · Summary checked against the source: 2026-11

Read or download the original

Adds to (doesn't replace) ESC/EAS 2019. Pages are from Eur Heart J 2025;46:4359–4378.

What's new

Topic Recommendation Class, level
Risk estimation SCORE2 (age <70) and SCORE2-OP (≥70) for 10-year fatal and non-fatal CVD risk in apparently healthy people I, B
CAC or subclinical plaque as a risk modifier at moderate risk or near decision thresholds IIa, B
Primary prevention Drug treatment for very high risk with LDL ≥1.8 mmol/L (70 mg/dL), or high risk with LDL ≥2.6 mmol/L (100 mg/dL) despite lifestyle I, A
Statin intolerance Non-statin therapies with proven CV benefit (ezetimibe, PCSK9 mAb, bempedoic acid), alone or combined I, A
Bempedoic acid when statins can't be taken I, B
Add bempedoic acid to maximal statin ± ezetimibe in high or very-high-risk patients not at goal IIa, C
Homozygous FH Evinacumab (anti-ANGPTL3) from age 5 if not at goal IIa, B
Acute coronary syndrome Intensify lipid-lowering during the index admission if already on treatment I, C
Treatment-naive and unlikely to reach goal on a statin alone: start high-intensity statin + ezetimibe in hospital IIa, B
Lp(a) >50 mg/dL (105 nmol/L) = a CV risk-enhancing factor in all adults, risk rising with the level IIa, B
Hypertriglyceridaemia Icosapent ethyl 2 g twice daily with a statin in high or very-high-risk patients with TG 135–499 mg/dL IIa, B
Volanesorsen 300 mg weekly for familial chylomicronaemia with TG >750 mg/dL IIa, B
HIV Statin for everyone ≥40 with HIV in primary prevention, whatever their risk or LDL-C (watch interactions) I, B
Cancer Statins in adults at high or very high risk of chemotherapy cardiotoxicity, to reduce anthracycline cardiac dysfunction IIa, B
Supplements Supplements or vitamins without proven safety and LDL-lowering efficacy: not recommended III, B

Adapted from ESC/EAS 2025 Recommendation Tables 1–8 [p. 4367–4374]

Expected LDL-C reduction ranges from about 20% with ezetimibe alone to about 85% with a high-intensity statin, ezetimibe and a PCSK9 mAb combined; response varies between people, so check LDL-C 4–6 weeks after any change. [Figure 2 · p. 4368]

Clinical pearls

  • SCORE2 / SCORE2-OP replace SCORE.
  • After ACS: "the sooner, the lower, the better": statin + ezetimibe can start in hospital.
  • Lp(a) >50 mg/dL is a risk enhancer.
  • All adults ≥40 with HIV get a statin.

Classes and levels of evidence

How ESC/EAS 2025 focused update grades its recommendations. Adapted from ESC/EAS 2025 focused update Tables 1 and 2 [p. 4362]. Hover over any class or level cited on this page to see what it means.

Class Meaning Wording used
Class I Evidence and/or general agreement that a treatment or procedure is beneficial, useful and effective is recommended or is indicated
Class IIa Weight of evidence or opinion is in favour of usefulness or efficacy should be considered
Class IIb Usefulness or efficacy is less well established by evidence or opinion may be considered
Class III Evidence or general agreement that the treatment or procedure isn't useful or effective, and in some cases may be harmful is not recommended
Level Meaning
Level A Data from multiple randomised clinical trials or meta-analyses
Level B Data from a single randomised clinical trial or large non-randomised studies
Level C Consensus of expert opinion and/or small studies, retrospective studies, registries

Class II covers conflicting evidence or a divergence of opinion about usefulness or efficacy. It's split into IIa and IIb.